Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma phenylethylamine in schizophrenic patients.

R O'Reilly1, B A Davis, D A Durden

  • 1Department of Psychiatry, St. Thomas Psychiatric Hospital, Ontario, Canada.

Biological Psychiatry
|July 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Genomics Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos.

Journal of equine veterinary science·2026
Same author

Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells.

Nature communications·2023
Same author

The Effects of a Walking Intervention on Gait Parameters in Older Adults Residing in Long-Term Care: A Randomized Controlled Trial.

The journal of nutrition, health & aging·2021
Same author

Upscaling e-mental health in Europe: a six-country qualitative analysis and policy recommendations from the eMEN project.

European archives of psychiatry and clinical neuroscience·2020
Same author

Dopaminergic and behavioural changes in a loss-of-imprinting model of Cdkn1c.

Genes, brain, and behavior·2017
Same author

Analysis of copper in brain by the mass-spectrometric integrated-ioncurrent procedure.

Neurochemical research·2013
Same journal

Domain-Derived Biomarkers of Treatment Response in Major Depressive Disorder: An Activation Likelihood Estimation Neuroimaging Meta-Analysis.

Biological psychiatry·2026
Same journal

Functional connectivity of orbitofrontal cortex predicts cocaine relapse: Protective and risk circuits, individual differences, and neuromodulation implications.

Biological psychiatry·2026
Same journal

Takeda G protein-coupled receptor 5 orchestrates anxiolysis by enhancing anterior paraventricular thalamic nucleus glutamatergic neuronal activity to engage distinct downstream circuits.

Biological psychiatry·2026
Same journal

Neuroimaging of Heterogeneity in Neuropsychiatric Disorders: Toward Disease Progression Modeling.

Biological psychiatry·2026
Same journal

Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial.

Biological psychiatry·2026
Same journal

Remembering Jon-Kar Zubieta, M.D., Ph.D.

Biological psychiatry·2026
See all related articles

This study found significantly higher plasma phenylethylamine (PE) levels in schizophrenia patients compared to healthy controls. These findings suggest PE may contribute to schizophrenia etiology, not just paranoid subtypes.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Psychiatry

Background:

  • Schizophrenia is a complex psychiatric disorder with debated etiological factors.
  • Previous research suggested elevated phenylethylamine (PE) in paranoid schizophrenia.

Purpose of the Study:

  • To investigate plasma PE levels in schizophrenia patients versus healthy controls.
  • To determine if PE levels correlate with symptom severity or subtype.

Main Methods:

  • Collected plasma samples from 41 schizophrenia patients and 34 healthy controls.
  • Quantified PE using gas chromatography-mass spectrometry (GC-MS).
  • Assessed symptom severity using BPRS, SANS, and SAPS.

Main Results:

  • Significantly higher plasma PE levels were observed in schizophrenia patients compared to controls.

Related Experiment Videos

  • No significant difference in PE levels between paranoid and nonparanoid schizophrenia subtypes.
  • Plasma PE levels did not correlate with symptom severity or dietary phenylalanine intake.
  • No correlation found between plasma PE and neuroleptic medication exposure, though confounding is possible.

    • Conclusions:

    • Elevated plasma PE may be implicated in the broader etiology of schizophrenia.
    • Findings do not support the hypothesis that PE abnormalities are exclusive to paranoid schizophrenia.
    • Further research is needed to clarify the role of PE and neuroleptic effects.